KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%

Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · Annals of Oncology · 2016

Cited by 17 works. doi:10.1093/annonc/mdw435.40 Open-access PDF

Authors